Seasonal Allergic Rhinitis
📧 Sign up to get email alerts when something new happens for Seasonal Allergic Rhinitis.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2025-06-27EMA Authorised: Avamys (fluticasone furoate) — GlaxoSmithKline Trading Services Limited
EMA has authorised Avamys (fluticasone furoate) nasal spray for allergic rhinitis, including seasonal and perennial forms.
-
CLINICAL_TRIALS trial_result · 2025-06-18Clinical Trial Update: A Motivation-enhancing App to Retain Patients With Hay Fever in a Trial After Treatment [NA]
This clinical trial update reports a completed study investigating a motivation-enhancing app aimed at retaining hay fever patients during a…
-
CLINICAL_TRIALS trial_result · 2025-06-11Clinical Trial Update: Phase II Study of JT002 in the Treatment of Seasonal Allergic Rhinitis in Adults [Phase 2]
Phase II clinical trial of JT002 for Seasonal Allergic Rhinitis in adults has completed.
-
CLINICAL_TRIALS research · 2025-05-25Clinical Trial Update: A Study to Assess the Efficacy and Safety of PG-011 Nasal Spray in Adults With Moderate to Severe Seasonal Allergic Rhinitis [Phase 2]
This document reports a Phase 2 clinical trial update for PG-011 nasal spray in adults with seasonal allergic rhinitis; the study is current…
-
CLINICAL_TRIALS trial_result · 2025-05-21Clinical Trial Update: Immunological Analysis of Lymph Node Tissue After Intralymphatic Immunotherapy: A Prospective Case Control Study [EARLY_Phase 1]
An early Phase 1 trial from the University of Zurich evaluated immunological changes in lymph node tissue after intralymphatic immunotherapy…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-05-21Clinical Trial Update: Intralymphatic Immunotherapy With Polvac Grass & Rye Allergen Extract [Phase 1, Phase 2]
This entry reports the completion of a Phase 1/2 clinical trial evaluating intralymphatic immunotherapy with Polvac grass and rye allergen e…
-
CLINICAL_TRIALS trial_result · 2025-04-25Clinical Trial Update: A Study of IL4Rα Monoclonal Antibody in Patients With Seasonal Allergic Rhinitis(SAR). [Phase 2]
Phase 2 study evaluating an IL4Rα monoclonal antibody for seasonal allergic rhinitis; the trial is currently listed as active but not recrui…
-
CLINICAL_TRIALS research · 2025-04-18Clinical Trial Update: Phase II/III Seamless Clinical Study of MG-K10 Humanized Monoclonal Antibody Injection in Treatment of Seasonal Allergic Rhinitis [Phase 2, Phase 3]
A phase II/III seamless clinical trial evaluating MG-K10, a humanized monoclonal antibody, for seasonal allergic rhinitis, currently in recr…
-
FDA approval · 2025-04-17FDA Approved: CLARITIN CHEWABLE GRAPE AND BUBBLEGUM — Supplemental Application (Bayer HealthCare LLC.)
FDA approved a supplemental application to introduce Claritin Chewable Grape and Bubblegum (loratadine) by Bayer HealthCare LLC. This approv…
-
FDA approval · 2025-04-03FDA Approved: MONTELUKAST SODIUM — Supplemental Application (Torrent Pharmaceuticals Limited)
FDA approved Torrent Pharmaceuticals Limited's supplemental application for montelukast sodium (ANDA 201515), enabling the approval of a gen…
-
CLINICAL_TRIALS trial_result · 2025-04-02Clinical Trial Update: Efficacy and Safety of PQ Grass in Subjects With Seasonal Allergic Rhinitis and/or Rhinoconjunctivitis Induced by Grass Pollen [Phase 3]
Phase 3 trial evaluating PQ Grass for grass pollen–induced seasonal allergic rhinitis and rhinoconjunctivitis completed with results posted.
-
FDA approval · 2025-02-28FDA Approved: OLOPATADINE HYDROCHLORIDE — Original Application (GLENMARK THERAPEUTICS INC., USA)
The FDA approved Glenmark Therapeutics' olopatadine hydrochloride as an original ANDA, permitting the marketing of a generic product.
-
CLINICAL_TRIALS trial_result · 2025-02-14Clinical Trial Update: Threshold Concentrations for Ragweed and Birch Pollen in Seasonal Allergic Rhinitis [NA]
A clinical trial evaluating threshold pollen concentrations for ragweed and birch pollen in seasonal allergic rhinitis has completed.
-
CLINICAL_TRIALS other · 2025-01-09Clinical Trial Update: Breathe-Easy: Hayfever Care for Patients With Seasonal Allergic Rhinitis [NA]
Clinical trial update for Breathe-Easy Hayfever Care in seasonal allergic rhinitis; status shows completed, with no results details provided…
-
FDA approval · 2024-10-24FDA Approved: CHILDRENS FLONASE ALLERGY RELIEF — Supplemental Application (Haleon US Holdings LLC)
FDA approved a supplemental application for Children's Flonase Allergy Relief (fluticasone propionate) from Haleon US Holdings LLC.
-
CLINICAL_TRIALS trial_result · 2024-10-17Clinical Trial Update: Factors Involved in Dymista's Superior Clinical Efficacy in the Treatment of Seasonal Allergic Rhinitis [Phase 4]
A Phase 4 clinical trial update reports superior efficacy of Dymista (azelastine hydrochloride and fluticasone propionate nasal spray) in tr…
-
CLINICAL_TRIALS trial_result · 2024-08-15Clinical Trial Update: An Approved Drug to Study a New Indication for Allergic Rhinitis (0476-327) [Phase 3]
Phase 3 trial update on an approved drug being studied for a new indication in seasonal allergic rhinitis.
-
CLINICAL_TRIALS trial_result · 2024-08-15Clinical Trial Update: An Approved Drug to Study a New Indication for Seasonal Allergic Rhinitis in Patients With Asthma (0476-269) [Phase 3]
This update reports the completion of a Phase 3 trial investigating a new indication for an approved drug to treat seasonal allergic rhiniti…
-
CLINICAL_TRIALS trial_result · 2024-08-15Clinical Trial Update: Efficacy and Safety of Desloratadine vs. Fexofenadine 180 mg. vs. Placebo for Treating Seasonal Allergic Rhinitis (SAR) (Study P04054) [Phase 4]
Phase 4 randomized trial comparing desloratadine, fexofenadine 180 mg, and placebo for seasonal allergic rhinitis. The study assessed effica…
-
CLINICAL_TRIALS trial_result · 2024-08-15Clinical Trial Update: Efficacy and Safety of Desloratadine vs. Fexofenadine 180 mg. vs. Placebo for Treating Seasonal Allergic Rhinitis (SAR)(Study P04053)(COMPLETED) [Phase 4]
A Phase 4 randomized trial comparing desloratadine, fexofenadine 180 mg, and placebo for seasonal allergic rhinitis, assessing efficacy and …
-
CLINICAL_TRIALS trial_result · 2024-08-15Clinical Trial Update: Effects of Loratadine/Montelukast vs Pseudoephedrine and Placebo in Patients With Seasonal Allergic Rhinitis (Study P04095) (COMPLETED) [Phase 3]
Phase 3 trial evaluating loratadine/montelukast versus pseudoephedrine and placebo for seasonal allergic rhinitis has completed.
-
CLINICAL_TRIALS trial_result · 2024-08-15Clinical Trial Update: Effect of Loratadine/Montelukast Combination on Congestion in SAR Patients Exposed to Pollen in an EEU (Study P04822) [Phase 3]
Phase 3 trial evaluating the loratadine/montelukast combination for congestion in Seasonal Allergic Rhinitis patients exposed to pollen; the…
-
CLINICAL_TRIALS trial_result · 2024-08-15Clinical Trial Update: Comparison of the Effects of Desloratadine and Placebo in the Relief of Nasal Symptom Scores in Subjects With Seasonal Allergic Rhinitis to Cypress Pollen (Study P02836) [Phase 4]
A Phase 4 randomized trial comparing desloratadine to placebo for relief of nasal symptoms in seasonal allergic rhinitis due to Cypress poll…
-
CLINICAL_TRIALS trial_result · 2024-08-15Clinical Trial Update: Preference for Clarinex Tablets vs. Allegra Tablets in Patients With Seasonal Allergies (Study P03177) [Phase 4]
Phase 4 trial comparing Clarinex (desloratadine) tablets to Allegra (fexofenadine) tablets for seasonal allergic rhinitis has completed.
-
CLINICAL_TRIALS trial_result · 2024-05-16Clinical Trial Update: A Placebo-controlled Study of 2-day Pre-treatment With Fexofenadine in Seasonal Allergic Rhinitis [Phase 3]
A Phase 3 placebo-controlled trial evaluated two-day pre-treatment with fexofenadine for seasonal allergic rhinitis, and the results have be…